Krystal Biotech KRYS Cash Flow Statement (2016-2026)

NASDAQ KRYS
$357.00 -14.47 (-3.90%)
As of: Sep 4, 2026 · 3:15 PM EDT
Reported Financials

Krystal Biotech Quarterly Cash Flow Statement

Periods 40 quarters
Latest Jun 2026

Krystal Biotech reported cash from operations of $74.79M and free cash flow of $71.22M for the quarter ended Jun 2026, up 41.8% year over year. This cash flow statement covers 40 quarters of results from Sep 2016 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-15.64M-22.02M-51.26M-29.10M-31.38M-28.24M-48.25M-33.21M80.75M8.69M0.93M15.57M27.17M45.51M35.70M38.33M79.37M51.39M55.93M54.77M
Share-based CompensationStock Comp.
3.67M5.14M6.43M8.19M9.06M9.55M10.44M11.33M8.31M9.85M9.30M13.16M13.32M13.36M13.48M14.12M13.15M13.76M13.61M14.16M
Deferred Taxes
-1.83M
Cash from OperationsCash from Ops.
-7.25M-20.90M-15.49M-43.06M-19.69M-22.33M-26.16M-34.19M-21.23M-7.23M15.89M-4.17M58.86M52.84M30.97M52.73M39.66M77.51M80.38M74.79M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.22M0.22M0.23M0.23M0.18M0.19M0.19M0.19M0.22M0.19M0.21M0.20M0.20M0.21M
Depreciation & Amortization (CF)Dep. & Amort.
0.78M0.78M1.01M0.98M0.97M1.09M0.70M1.04M0.83M
Change in Working Capital
Change in ReceivablesChange Receivables
9.32M32.72M4.43M56.77M-5.94M7.45M-1.49M8.18M17.92M-2.49M-0.06M11.97M
Change in InventoryChange Inventory
0.91M3.08M0.49M2.24M-0.53M3.68M6.52M1.40M-0.88M4.71M1.06M0.24M0.96M
Change in Account PayablesChange Payables
0.46M0.94M-0.55M0.58M-0.34M-0.94M0.11M0.37M-0.36M-0.22M0.73M0.78M0.09M-0.59M0.91M4.12M-4.02M-0.18M1.02M3.06M
Change in Accured ExpensesChange Accured Exp.
3.93M-4.02M2.01M0.46M0.54M2.16M-3.46M1.80M2.54M3.68M-5.16M1.13M1.94M7.48M3.69M-1.29M5.92M5.79M-6.31M5.44M
Change in TaxesChange Taxes
0.97M-0.46M1.41M9.15M2.29M-3.37M4.67M
Investing Activities
Capital ExpendituresCapex
17.31M40.88M17.19M16.52M14.06M5.22M11.87M-0.87M0.10M0.70M8.46M0.11M-0.28M0.20M6.20M1.90M1.70M2.14M7.15M3.56M
Sales of Property, Plant and EquipmentPP&E (Sale)
0.43M
Change in Acquisitions & DivestmentsChange Acquisitions
8.07M21.00M24.04M62.79M66.77M104.08M154.52M161.23M112.87M74.59M63.62M95.18M79.25M60.49M88.81M105.28M95.79M85.76M103.60M100.00M
Cash from Investing ActivitiesCash from Investing
-37.17M-126.54M-55.91M-38.22M-14.74M-5.21M3.56M-15.96M105.19M-10.16M-25.98M-19.35M-34.33M-83.78M-54.77M-10.53M-4.29M11.16M-63.58M-161.58M
Financing Activities
Other financing activitiesOther financing
2.22M25.43M13.51M2.61M15.97M10.64M3.37M2.43M1.46M1.80M3.71M15.69M6.50M15.16M
Cash from Financing ActivitiesCash from Financing
1.51M202.07M-0.54M30.70M2.12M3.07M1.47M185.27M13.39M2.62M10.58M10.64M3.37M2.43M-12.47M1.80M3.71M15.67M-10.46M15.05M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
1.51M202.07M0.11M30.70M2.12M-3.94M2.22M157.62M-0.12M0.01M
Additional items
Exchange Rate EffectFX Effect
-0.04M-0.04M0.01M0.01M-0.14M0.19M-0.34M0.29M-0.59M0.17M1.06M-0.31M-0.64M-1.33M-1.83M
Change in Cash
-42.91M54.63M-71.94M-50.58M-32.31M-24.51M-21.16M135.13M97.37M-14.91M0.68M-13.22M28.18M-29.10M-36.09M45.06M38.77M103.70M5.01M-73.57M
Free Cash FlowFCF
-24.57M-61.78M-32.68M-59.57M-33.74M-27.55M-38.02M-33.32M-21.33M-7.93M7.43M-4.28M59.13M52.64M24.77M50.83M37.95M75.37M73.23M71.22M
Net Cash FlowNCF
-42.91M54.63M-71.94M-50.58M-32.31M-24.47M-21.12M135.12M97.35M-14.77M0.49M-12.88M27.89M-28.51M-36.27M44.00M39.08M104.34M6.34M-71.74M